Kornimate/medical-research-clean huggingface dataset:
investigating participation patterns among recurrent ovarian cancer patients

Conditions: Recurrent Ovarian Cancer

Summary: clinical trials, with a particular focus on recurrent ovarian cancer, play a crucial role in assessing the safety and efficacy of novel treatments for this condition. these trials serve as essential tools to determine whether new medications outperform traditional therapies, providing substantial evidence to support their widespread adoption. by actively participating in recurrent ovarian cancer observational study serves pivotal role in expanding the boundaries of medical knowledge and advancing the quality of care provided to those enduring the same condition.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years old * able to comprehend the investigational nature of the protocol and provide informed consent * diagnosis of recurrent ovarian cancer exclusion criteria: * no diagnosis of recurrent ovarian cancer confirmed * inability to perform regular electronic reporting * patient does not understand, sign, and return consent form

Keywords: recurrent ovarian cancer
development of a new prognostic assessment tool for postoperative myocardial injury

Conditions: Perioperative Complication; Myocardial Injury

Summary: myocardial injury after noncardiac surgery (mins) is common, silent, and strongly associated with morbi-mortality. there are some evidences in the littérature showing that troponin elevation pre and/or postoperatively and surgical apgar score are strongly and independently associated with postoperative morbi-mortality. in this cohort study of orthopedic surgery patients (\> 50years), the aim is to determine mins incidence and to assess wich peri-operative factors are associated with the occurrence of mins. the final objective is to create a score to better identified the patients with a mins and a poor outcome.


Eligibility criteria:
inclusion criteria: * \> 50 years * orthopedic surgery (hip, knee, spine) * written consent exclusion criteria: * no troponin measurement prior surgery * sepsis * acute coronary syndrome * pulmonary embolism * refusing to participate * guardianship

Keywords: non cardiac surgery
metformin glycinate, treatment of patients with covid-19 and severe acute respiratory syndrome secondary to sars-cov-2.

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2

Summary: the purpose of this study is to evaluate the efficacy and safety of the metformin glycinate and standard treatment of the hospital in hospitalized patients with severe acute respiratory syndrome secondary to sars-cov2.

after being informed about the study and potential risks, all patients giving written informed consent will undergo a 1 day screening period to determine eligibility for study entry. at day 0, patients who meet the eligibility requirements will be randomized in a double blind manner (participant and investigator) in a 1:1 ratio to metformin glycinate (620 mg, taken orally, twice daily) plus standard treatment or placebo (taken orally, twice daily) plus standard treatment, both for 14 days.

Eligibility criteria:
inclusion criteria: 1. ≥ 18 years old 2. ability to understand and the willingness to sign a written informed consent document before any study procedure 3. coronavirus infection, severe acute respiratory syndrome (sars-cov)-2 confirmed by the polymerase chain reaction (pcr) test ≤ 4 days before randomization. 4. hospitalized 5. radiographic evidence of pulmonary infiltrates exclusion criteria: 1. participation in any other clinical trial of an experimental treatment for covid-19 2. evidence of multi-organ failure 3. require mechanical ventilation before randomization 4. pregnant patients 5. patients with kidney failure, cancer and among other conditions that due to their treatment and / or baseline condition, affect the distribution, bioavailability and elimination of the studied drug

Keywords: sars-cov 2 severe acute respiratory syndrome
cutaneous heart sounds data collection during cardiac resynchronization therapy (crt) optimization study

Conditions: Heart Failure

Summary: the cutaneous heart sounds data collection during crt optimization study is an acute, prospective, non-randomized multi-center feasibility clinical trial. the purpose of this clinical trial is to collect data to assist in the testing and finalization of a hemodynamic sensor-based cardiac resynchronization therapy (crt) optimization scheme.


Eligibility criteria:
inclusion criteria: * subject must have been implanted with a medtronic market approved crt-d device (concerto®, concerto® ii, maximo® ii, consulta®, protecta™, or protecta™ xt) within two years * subject must be 18 years of age or older * subject or his/her legally authorized representative has signed and dated the study specific informed consent form ("consent form") * subject is willing and able to comply with protocol requirements exclusion criteria: * subject with atrial tachyarrhythmia or frequent atrial or ventricular ectopy * subject is post mitral or aortic valve repair or replacement * subject is participating in other research studies that many confound the results of this study * subject is pregnant or in fertile age without secure birth control * subject has dementia * subject is unwilling to comply with protocol requirements * subject has a device and lead system with fractured leads * subject cannot undergo an echocardiograph procedure, or is contraindicated to undergo such a procedure

Keywords: cardiac resynchronization therapy defibrillator (crt-d) devices
safety and efficacy of tocilizumab in moderate to severe covid-19 with inflammatory markers

Conditions: COVID; SARS Pneumonia; Cytokine Release Syndrome

Summary: the trial evaluates the efficacy and safety of tocilizumab, which rapidly reduces the inflammation process through inhibition of il-6 in patients with moderate to severe covid-19 with increased inflammatory markers. there will be two arms in the trial, one receiving the best supportive care, and the other receiving it plus tocilizumab. patients will be followed until day 29 after randomization.

coalition vi (tocibrás) is a prospective phase iii randomized controlled trial that evaluates the efficacy and safety of tocilizumab, an antibody anti-il-6 receptor in patients with moderate to severe covid-19 with increased inflammatory markers. this is a superiority open-label study with two arms. the control arm receives the best supportive care, and the experimental receives it plus tocilizumab. randomization is done centrally by redcap 1:1. patients will be followed until day 29 after randomization.

Eligibility criteria:
inclusion criteria: * male and females with 18 years and older * confirmed diagnosis of sars-cov 2 infection * more than 3 days of symptoms related to covid-19 * computed tomography (or chest x-ray) with covid-19 alterations * both of the criteria 1. need for oxygen supplementation to keep spo2 \> 93% or need for mechanical ventilation for less than 24 hours before the randomization 2. at least two of the following inflammatory tests above the cutoff : 1. d-dimer \> 1,000 ng/ml 2. reactive c protein \> 5 mg/dl 3. ferritin \> 300 mg/dl 4. lactate dehydrogenase \> upper level limit exclusion criteria: * need for mechanical ventilation for 24 hours or more before the randomization * hypersensitivity to tocilizumab * patients without therapeutic perspective or in palliative care * active non controlled infections * other clinical conditions that contraindicate tocilizumab, according to the assistant physician * low neutrophils count (\< 0.5 x 109/l) * low platelets count (\< 50 x 109/l) * liver disease, cirrhosis or elevated ast or alt above 5 times the upper level limit * renal disease with estimate glomerular filtration below 30 ml/min/1.72 m2 (mdrd or ckd-epi scores) * active diverticulitis * breastfeeding women * pregnancy

Keywords: sars-cov 2 sars pneumonia tocilizumab cytokine release syndrom interleukin-6 hyperinflammation
meclizine plasma levels in responders and non-responders

Conditions: Seasickness; Meclizine

Summary: motion sickness is a debilitating condition that can effect many crew members. meclizine has long been known as an effective anti motion sickness drug. the response to the drug is variable - some are responders, while others are resistant to the drug. the aim of the present study is to examine whether there is a correlation between meclizine plasma levels and clinical response.


Eligibility criteria:
inclusion criteria: * seasickness questioner (wiker) score of 7. * subjective functioning at 1 meter sea voyage - 5/10 and lower. * subjects who were prescribed 25mg of meclizine. * subjects who did not take any other drugs 48 prior to their participation in the study. exclusion criteria: * known hearing loss or any vestibular impairment * vertigo complains * any ear infection * use of scopolamine based anti-seasickness drugs. * use of meclizine 50mg.

Keywords: seasickness plasma levels meclizine
zero ischemia laparoscopic partial nephrectomy

Conditions: Small Renal Mass

Summary: laparoscopic partial nephrectomy (lpn) is often reserved for patients with a small peripheral tumour, in the hands of an experienced surgeon since it demands a high degree of endoscopic skill. renal vessel clamp for vascular control is a required step during standard lpn. however, this creates a time limiting step for the surgeon and induces renal injury via warm ischemia and reperfusion injury. this novel approach can substantially reduce renal injury during lpn via superselective embolization of level ii renal arteries pre-operatively. this technique facilitates the performance of a clamp-less, zero-ischemia lpn, significantly simplifying the procedure by remove time thresholds within which to perform tumor excision. the preliminary results are promising; however, there is a need for further corroboration of their results, in addition to a randomized controlled trial comparing this modified, zero ischemia technique with standard lpn.

the potential utility of a zero ischemia, laparoscopic, partial nephrectomy portends significant implications for both the surgeon and patient. firstly, the technical difficulty of a partial nephrectomy will be reduced to a more achievable level owing mainly to the removal of a time limit on surgical resection. with the blood flow halted to downstream tissue containing the renal neoplasm from preoperative embolization, resection can be made to the tumor without clamping of the main renal arteries. this minimizes the ischemic time to non-neoplastic renal tissue, allowing for a renal protective effect. without the need for clamping, the overall surgical operative time is drastically reduced. with excision made at the ischemic tissue, intra-operative bleeding and ease can be achieved. more surgeons can ultimately attempt at lpn by removing the single most limiting surgical factor, warm ischemic time.

Eligibility criteria:
inclusion criteria: * t1a renal cell carcinomas diagnosed by ultrasonography (us), computed tomography (ct) or fine needle aspiration * tumor size \<4cm in diameter * predominant exophytic growth * intraparenchymal depth no greater than 1.5cm, with a minimum distance of 5mm from the urinary collecting system exclusion criteria: * predominant endophytic nature (depth \</= 1.5 cm) * nearness (\<0.5cm) of the tumor to the urinary collecting system * multiple ipsilateral lesions * pregnancy * allergy to intravenous contrast dye * absolute contraindications to surgical intervention
t2 biomarkers predictive value in occupational asthma after cessation of exposure.

Conditions: Asthma; Occupational Asthma; Occupational Diseases

Summary: occupational exposure is known to cause 15% of asthma cases. the main treatment for occupational asthma is to stop exposure if possible. although, remission of occupational asthma only occurs in only 30 % of patients after cessation of exposure. there is currently no way of predicting which patients will go into remission after cessation of exposure. in non-occupational asthma, the inflammatory biomarker t2 has allowed the entry into personalized medicine and can predict future exacerbations. the investigators hypothesize that t2 biomarkers could be predictive markers for remission in occupational asthma after exposure cessation. the investigators intend to carry out a follow-up study at the university hospital of strasbourg to perform the non-specific bronchial hyperresponsiveness test to assess remission in patients diagnosed with occupational asthma and to compare baseline t2 biomarkers in remission and non remission patients.


Eligibility criteria:
inclusion criteria: * age over 18 * diagnosis of occupational asthma by specific inhalation challenge * exposure to sensitizing agent avoided or reduced * able to understand the aims and risks of the research and to give free and informed consent * for women of childbearing age: effective contraception in progress. * benefiting from social security coverage exclusion criteria: * impossibility of giving the subject informed information (subject in emergency situation, difficulties in understanding the subject) * subject under court protection * subject under guardianship or curatorship * pregnant or breast-feeding patient
a cohort study in newly diagnosed mzl

Conditions: Marginal Zone Lymphoma

Summary: describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of marginal zone b-cell lymphoma (mzl), observe the therapeutic efficacy and safety of different treatment modalities.

marginal zone lymphoma (mzl) originates from the marginal zone of lymphatic follicles and can occur in the spleen, lymph nodes and mucosal lymphoid tissues, and the incidence increases with age. the clinicopathological features of each subtype of mzl are heterogeneous, and their clinical manifestations, biology, etiology, and treatment are all quite heterogeneous, and there is still significant uncertainty about the optimal treatment pathway. this prospective, multicenter, cohort study aims to describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of mzl, and to observe the therapeutic efficacy and safety of different treatment modalities.

Eligibility criteria:
inclusion criteria: * age≥ 18 years old; male or female. * newly diagnosed marginal zone lymphoma by histopathology within the past 6 months (180 days) and no anti-tumor therapy (including chemotherapy, radiotherapy, and biological therapy or immunotherapy for the treatment of tumors). * willing to provide biological samples required for the study, including blood samples and tumor tissue. * voluntarily join this study and sign the informed consent form. * willing to accept long-term follow-up. exclusion criteria: * patients with hiv infection. * those who cannot come to the hospital regularly for follow-up. * those with comorbidities and speech impairment.
exercise-training before coronary artery bypass graft (cabg)

Conditions: Angina; Coronary Artery Disease

Summary: the aim is to evaluate the effect of exercise training upon endothelial function in the mammary artery of patients who are scheduled for cabg, as well as study the functional properties of single cells isolated from a small biopsy of the left ventricle obtained during surgery.


Eligibility criteria:
inclusion criteria: * scheduled for cabg both with and without heart failure exclusion criteria: * unstable angina * unable to walk on a treadmill (except those with heart failure who only will serve as a reference group) * participation in another study

Keywords: aerobic capacity exercise training cabg endothelial function
management of large retained products of conception (> 4 cm): need for an standardized procedure.

Conditions: Placenta, Retained; Placenta; Retention, Fragments, Complicating Puerperium, Without Hemorrhage; Placenta; Retention, Fragments, Complicating Puerperium (Delayed Hemorrhage); Pregnancy Related; Hysteroscopy / Methods; Retrospective Studies; Vacuum Curettage

Summary: collection of relevant data form patients who were treated in the ghent university hospital in the context of a placental remnant lager than 4 cm, performing statistical analyzes on the collected data, reviewing the literature on the subject and formulation of a recommendation for treatment of these large placental remnants.


Eligibility criteria:
inclusion criteria: * retained products of conception larger than 4 cm in largest dimension exclusion criteria: * retained products of conception 4 cm or smaller in largest dimension
dyslipidemia prevalence, perception, treatment, and awareness in the tunisian population

Conditions: Dyslipidemias; Atherosclerosis; Households; Survey, Family Life

Summary: atera survey is a national cross sectional observational study, aiming to determine the prevalence of dyslipidemia and other conventional risk factors for chd (coronary heart disease), the relationship between environmental and lifestyle factors with dyslipidemia, the perception and the knowledge of cardiovascular risk factors by the population, and above all, to strengthen the national strategy for primary and secondary prevention against coronary heart disease.

atera survey is carried on in a random sampling including 10 000 men and women from the seven regions of tunisia (great tunis, north east, north west, central east, central west, south east and south west. the screening is being assessed using surveys covering socioeconomic, nutritional and anthropometric measures in addition to biological assessments. the target population is being recruited by random sampling drown by the national institute of statistics (tunisia). the estimated number of participants at the end of recruitment amount to 10 000. the frame sampling uses a two stage cluster sampling (district and household). interview with each eligible participant will be conducted mainly during assessment visit and after consenting the subject, it will be notified all the demographic, behavioral history, family history, cardiovascular risk factors and medical history. during the assessment visit, physical examination/anthropometry data and diet survey will be filled up by the investigator. data capture will be performed by the dacima clinical suite according to fda 21 cfr part 11 requirements (food and drug administration 21 code of federal regulations part 11), the hipaa specifications (health insurance portability and accountability act), and the ich standards (international conference on harmonisation)

Eligibility criteria:
inclusion criteria: * all subjects exclusion criteria: * prescribed treatment for cancer * organ transplantation * known auto-immune disease * severe liver disease * chronic renal failure * pregnant women

Keywords: coronary heart disease hypercholesterolemia triglycerides high ldl hyperlipoproteinemia hdl low diabetes cardiovascular diseases hypertension risk factor, cardiovascular diet habit smoking
functional outcome following surgical treatment of patients with sternoclavicular joint infection

Conditions: Sternoclavicular Joint Infection

Summary: the sternoclavicular joints (scj) represents an important factor in stability of shoulder joint. its influence and its function is important for the functionality of the shoulder. scj infection is a rare condition and remains often mistreated and potentially life threatening. this study is to assess the cases treated at the university hospital basel with a surgical approach of extended resection of the scj. one prospective follow-up visit inclusive one physical examination per patient will be performed to evaluate the long-term functional results of arm, shoulder, hand function with the quickdash questionnaire.


Eligibility criteria:
inclusion criteria: * patient assigned and treated at the department of thoracic surgery, university hospital basel (usb) * at hospital admission diagnosed with clinical characteristics of sternoclavicular joint infection * surgical treatment of extended scj resection received * signed written informed consent according to ich-gcp regulations prior to initiation of any protocol-specific activities/procedure * patients who died will be included if a signed usb general research consent is available exclusion criteria: * isolated sternal or clavicular infection * patients received other surgery than extended scj resection at usb thoracic surgery * inability to follow procedures or insufficient knowledge of language (german/french) or inability to give consent * patients who have clearly stated that they would not agree in providing their clinical data for scientific purposes

Keywords: quickdash questionnaire extended scj resection
the bern perioperative biobank

Conditions: Anesthesia; Surgical Procedure, Operative

Summary: the goal of the research is to define clinically relevant molecular markers for increased risk of peri-/ postoperative organo-dysfunctions, inflammation, adverse events and disease progression. to better understand the perioperative impact the investigators aim to determine perioperative levels of molecular markers over time in the available samples and clinical data of the bern perioperative biobank (bpbb) cohort to finally increase quality of perioperative care of patients by permitting preventive measures to be taken early in patients at risk.


Eligibility criteria:
inclusion criteria: * 18 years and older * written informed consent * non-emergency surgery exclusion criteria * transient incapacity to consent or insufficient time (\< 6h) to consider study participation * no informed consent * cognitive impairment/patients unable to consent * patients who retrospectively expressed their wish to be excluded

Keywords: genetic association study
a personalized, digital coaching program after stroke

Conditions: Stroke, Ischemic

Summary: the belgian stroke council initiated a project to improve risk factor control and medication adherence in ischemic stroke patients by developing an individualized in-hospital initiated and post- discharge, digital coaching program addition to standard practice (strokecoach.be).

the overall aim of this project is to further improve subacute and chronic stroke care in the belgian context with main focus on the patients' quality of life, stroke recurrence and secondary cardiovascular prevention. main focuses are on patient-empowerment, shared-decision making and health literacy, as these items are linked with better therapeutic adherence and self-care for chronic diseases. in case of a positive result, implementation of this individualized chronic stroke care program executed by a personal stroke coach, initiated during hospitalization and using a web-based intervention program, can easily be unrolled in other belgian stroke units. the program can be cost-effective if better clinical outcome, stroke recurrence rates, number of in-hospital consultations, number of rehospitalisations are reduced. this will be evaluated in a in-depth healt-economic analysis.

Eligibility criteria:
inclusion criteria: patients with an acute ischemic stroke hospitalized at a participating stroke center can be included during hospitalisation if fulfilling following three criteria: - they will return back home or be discharged to a rehabilitation center * have a life expectancy of more than 6 months * have experience with internet use (at least weekly checking emails) or a caregiver accepts to help with the digital platform. exclusion criteria: * age \< 18 years * patients unable or unwilling to be followed post-discharge for 6 months * patients with a major neurologic post-stroke and no caregiver participation * cognitive impairment limiting use of digital platform and no caregiver participation

Keywords: secondary prevention web-based intervention strokecoach